Biotest AG
XETRA:BIO

Watchlist Manager
Biotest AG Logo
Biotest AG
XETRA:BIO
Watchlist
Price: 41.4 EUR Market Closed
Market Cap: 1.6B EUR
Have any thoughts about
Biotest AG?
Write Note

Biotest AG
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biotest AG
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Biotest AG
XETRA:BIO
Cash Equivalents
€24.7m
CAGR 3-Years
-32%
CAGR 5-Years
-18%
CAGR 10-Years
-11%
BioNTech SE
NASDAQ:BNTX
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
MorphoSys AG
XETRA:MOR
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CureVac NV
NASDAQ:CVAC
Cash Equivalents
€402.5m
CAGR 3-Years
-33%
CAGR 5-Years
80%
CAGR 10-Years
N/A
Immatics NV
NASDAQ:IMTX
Cash Equivalents
€218.5m
CAGR 3-Years
2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Formycon AG
XETRA:FYB
Cash Equivalents
€27m
CAGR 3-Years
-14%
CAGR 5-Years
30%
CAGR 10-Years
N/A
No Stocks Found

Biotest AG
Glance View

Market Cap
1.6B EUR
Industry
Biotechnology

Biotest AG, headquartered in Dreieich, Germany, is a pivotal player in the field of biopharmaceuticals, with a particular focus on blood plasma-derived products. The company traces its origins back to 1946 when it was founded as a laboratory for blood testing, and since then, it has transformed into a significant force in the healthcare sector. Biotest operates on a vertically integrated business model, from collecting plasma to the manufacturing and distribution of therapeutic proteins. The company primarily produces and markets products like immunoglobulins, coagulation factors, and albumins, which are essential for treating immune system deficiencies, blood clotting disorders, and various other ailments. These products serve not only to improve the quality of life for patients but are critical lifelines for those with chronic and acute conditions. Revenue generation at Biotest revolves around a three-pronged strategy: plasma collection, manufacturing, and commercialization of its proprietary therapies. The process begins with the acquisition of raw plasma through an extensive network of collection centers. This plasma is then processed and transformed into high-value therapeutic products in sophisticated manufacturing facilities. Biotest’s revenue stream is bolstered by its strong presence in international markets, serving hospitals, clinics, and healthcare systems with high demand for its specialized products. By leveraging its in-depth expertise in plasma technology and robust infrastructure, Biotest AG has carved a niche, ensuring a steady flow of returns while contributing significantly to advancements in treating rare diseases and fostering global health betterment.

BIO Intrinsic Value
32.12 EUR
Overvaluation 22%
Intrinsic Value
Price

See Also

What is Biotest AG's Cash Equivalents?
Cash Equivalents
24.7m EUR

Based on the financial report for Sep 30, 2024, Biotest AG's Cash Equivalents amounts to 24.7m EUR.

What is Biotest AG's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
-11%

Over the last year, the Cash Equivalents growth was -62%. The average annual Cash Equivalents growth rates for Biotest AG have been -32% over the past three years , -18% over the past five years , and -11% over the past ten years .

Back to Top